Anticoagulanttherapyisacornerstoneinmanagingthromboembolicrisksacrossdiverseclinicalscenarios,fromperioperativecaretochronicdiseasemanagement.Amonglowmolecularweightheparins(LMWHs),EnoxaparinSodiumand
Anticoagulanttherapyplaysavitalroleinpreventingandtreatingthromboembolicdiseases,andthedemandforsafe,effective,andpopulation-specificanticoagulantsisincreasinglyprominentinclinicalpractice.Asalowmolec
Asacornerstonelowmolecularweightheparin(LMWH),EnoxaparinSodiumiswidelyrecognizedasthefirst-linetherapyforpreventingandtreatingvenousthromboembolism(VTE),supportingcardiovascularsurgeries,andmanaginghe
Anticoagulanttherapiesstandasacornerstoneinmanagingthromboticdisorders,whichaccountforasignificantportionofglobalcardiovascularmortality.Heparins,includingunfractionatedheparin(UFH)andlowmolecularweig
Venousthromboembolism(VTE)remainsalife-threateningcomplicationinpatientswithrenalimpairment,whofaceadualchallengeofelevatedthromboticriskandincreasedbleedingsusceptibility.Anticoagulanttherapyinthispo